BM
Bristol-Myers Squibb
BMY·NYSEPrinceton NJFounded 188734,000 employees
Large CappharmaPublicOncologyHematologyImmunologyCardiology
Platform: IO & Cell
Market Cap
$95B
All Drugs
13
Clinical Trials
28
Failed / Terminated
4
FDA Approved
2
Stock Price & Catalysts (BMY)
Loading BMY stock data...
Drug Pipeline (13 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Ivocapivasertib | BMY-6497 | Phase 1 | 2 | BET | Parkinson's | ||
| BMY-3371 | BMY-3371 | Phase 3 | 2 | WRN | SMACF | ||
| BMY-2495 | BMY-2495 | Phase 3 | 1 | KRASG12D | Hemophilia ADLBCL | ||
| Gozesotorasib | BMY-2236 | NDA/BLA | 2 | HER2 | Hemophilia AHeart Failure | ||
| BMY-7975 | BMY-7975 | Phase 1 | 1 | MALT1 | Urothelial CaHS | ||
| Zorivorutinib | BMY-6101 | Approved | 4 | DLL3 | Prostate CaMM | ||
| Bemalucimab | BMY-4392 | Phase 1/2 | 2 | Aβ | PsA | ||
| BMY-9931 | BMY-9931 | Phase 1 | 1 | GPRC5D | ALLALS | ||
| BMY-8678 | BMY-8678 | Approved | 4 | RET | AS | ||
| Zanutinib | BMY-5015 | Phase 2/3 | 2 | APOC3 | SCLCIgAN | ||
| BMY-4586 | BMY-4586 | Preclinical | 2 | KRASG12C | MCCSCD | ||
| Doxarapivir | BMY-8798 | Phase 3 | 4 | KRASG12C | Huntington'sFTD | ||
| Zorimavacamten | BMY-8759 | Preclinical | 1 | Cl18.2 | Urothelial CaSMA |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (24)